VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 634 filers reported holding VANECK VECTORS ETF TR in Q3 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $651,613 | -0.7% | 24,215 | +11.1% | 0.02% | +20.0% |
Q2 2023 | $656,271 | -5.9% | 21,796 | +1.1% | 0.02% | -21.1% |
Q1 2023 | $697,340 | -43.7% | 21,556 | -50.1% | 0.02% | -45.7% |
Q4 2022 | $1,239,119 | +168.2% | 43,235 | +126.2% | 0.04% | +150.0% |
Q3 2022 | $462,000 | -62.5% | 19,116 | -57.5% | 0.01% | -73.1% |
Q2 2022 | $1,231,000 | -32.8% | 44,928 | -5.9% | 0.05% | -13.3% |
Q1 2022 | $1,831,000 | +165.4% | 47,720 | +121.7% | 0.06% | +200.0% |
Q4 2021 | $690,000 | +9.0% | 21,526 | +0.2% | 0.02% | 0.0% |
Q3 2021 | $633,000 | -9.8% | 21,478 | +4.0% | 0.02% | -13.0% |
Q2 2021 | $702,000 | +13.8% | 20,659 | +9.0% | 0.02% | +4.5% |
Q1 2021 | $617,000 | +7.9% | 18,955 | +19.4% | 0.02% | -29.0% |
Q4 2020 | $572,000 | -28.1% | 15,873 | -31.5% | 0.03% | -26.2% |
Q3 2020 | $795,000 | +104.4% | 23,174 | +73.6% | 0.04% | +61.5% |
Q2 2020 | $389,000 | -73.9% | 13,347 | -79.9% | 0.03% | -86.0% |
Q1 2019 | $1,488,000 | – | 66,337 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |